Clinical Theragnostic Relationship between Chemotherapeutic Resistance, and Sensitivity and miRNA Expressions in Head and Neck Cancers: A Systematic Review and Meta-Analysis Protocol
Abstract
:1. Introduction
2. Rationale
Review Questions
- What effect does miRNA regulation have on chemotherapy?
- What is the general prognosis of patients having miRNA-specific chemoresistance?
- What are the miRNAs most responsible for chemoresistance in HNC patients?
- What are the survival rates associated with each miRNA linked to chemoresistance, and how are they affected?
- How does the prognosis vary for different miRNA causing the chemoresistance?
- What is the future of miRNA as an active form of cancer treatment for Head and Neck Cancer?
3. Materials and Methods
3.1. Search Methods
3.2. Selection Criteria
3.2.1. Inclusion Criteria
- Studies analyzing the effect of miRNA expressions in both HNC patients and cell lines will be considered.
- Studies analyzing miRNAs and resistance/are performed in liquid biopsies (plasma, saliva....) will be included.
- Studies that discuss the clinicopathological characteristics of HNC patients along with hazard ratio or Kaplan–Meier curve will be included.
- Studies reporting resistance in HNC will be included.
- Articles that discuss the survival outcomes of almost all stages of HNC patients will be included in the meta-analysis.
- Studies reporting miRNA profiling platform and miRNA expressions analysis using in vitro assays will be included.
- Studies that differentiate between 3p and 5p in the microRNAs expressions in HNC
- Genes and/or pathways involved in chemoresistance or sensitivity in HNC patients will also be considered.
- miRNA expression analysis, HR, and associated 95% CI or Kaplan–Meier (KM) curve is required for the eligible studies.
- Studies appropriate to PRISMA guidelines for systematic review and meta-analysis will be included.
3.2.2. Exclusion Criteria
- Studies published in languages other than English.
- Any information or results from letters to the editors, case studies, conference abstracts, case reports, and review articles of HNC will be removed.
- Studies performed only in vitro will be excluded and will not be considered for the systematic review.
- Studies in which proper discussion about miRNA profiling and pathways related to that are not available will be excluded.
- Studies with no accessibility to survival outcomes, HR values, or Kaplan–Meier (KM) curve will not be considered for the meta-analysis.
- Studies using patients’ information from datasets or cancer registries will be removed.
- Studies whose full texts are not accessible will also be excluded.
- Duplicates will be removed, and the study will be excluded if it falls within the exclusion criteria.
3.2.3. Participants
3.3. Data Collection and Management
- Author name and information
- Type of head or neck cancer
- Date and journal of publication
- Type of micro-RNA studied
- Hazard Ratio and 95% Confidence Interval
- Patients origin (by country)
- Type/origin of Samples collected for analysis
- The total number of samples used
- Cell lines and the pathways affected
- Clinical stage of the affected HNC patients and their details
- Type of chemoresistant cells and chemoresistant drug
- Micro-RNA profiling platform
Data Items Included in this Study
- Characteristics of study material (author names, geographical area of study, type of study, year of publication)
- Characteristics of study participants (country of origin, clinical stage of cancer, type of expressed miRNA, drug to which resistance is expressed)
- Characteristics of study methods and results (miRNA profiling platform, number of samples, statistical analysis)
3.4. Study Selection Process
3.5. Study Outcomes
3.6. Mitigating Risk of Bias in Individual Studies
3.7. Data Synthesis
3.8. Meta-Analysis and Subgroup Analysis
3.9. Reporting of the Review
4. Discussion
5. Ethics and Dissemination
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Head and Neck Cancers-National Cancer Institute. Available online: https://www.cancer.gov/types/head-and-neck/head-neck-fact-sheet (accessed on 29 October 2021).
- Nakashima, H.; Yoshida, R.; Hirosue, A.; Kawahara, K.; Sakata, J.; Arita, H.; Yamamoto, T.; Toya, R.; Murakami, R.; Hiraki, A. Circulating miRNA-1290 as a potential biomarker for response to chemoradiotherapy and prognosis of patients with advanced oral squamous cell carcinoma: A single-center retrospective study. Tumor Biol. 2019, 41, 1010428319826853. [Google Scholar] [CrossRef] [Green Version]
- Yang, F.; Li, Y.; Xu, L.; Zhu, Y.; Gao, H.; Zhen, L.; Fang, L. miR-17 as a diagnostic biomarker regulates cell proliferation in breast cancer. Onco Targets Ther. 2017, 10, 543. [Google Scholar] [CrossRef] [Green Version]
- Wu, S.-G.; Chang, T.-H.; Liu, Y.-N.; Shih, J.-Y. MicroRNA in lung cancer metastasis. Cancers 2019, 11, 265. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chan, S.-H.; Wang, L.-H. Regulation of cancer metastasis by microRNAs. J. Biomed. Sci. 2015, 22, 9. [Google Scholar] [CrossRef] [Green Version]
- Shirjang, S.; Mansoori, B.; Asghari, S.; Duijf, P.H.; Mohammadi, A.; Gjerstorff, M.; Baradaran, B. MicroRNAs in cancer cell death pathways: Apoptosis and necroptosis. Free Radic. Biol. Med. 2019, 139, 1–15. [Google Scholar] [CrossRef] [PubMed]
- Rolfo, C.; Fanale, D.; Hong, D.S.; Tsimberidou, A.M.; Piha-Paul, S.A.; Pauwels, P.; Van Meerbeeck, J.P.; Caruso, S.; Bazan, V.; Cicero, G. Impact of microRNAs in resistance to chemotherapy and novel targeted agents in non-small cell lung cancer. Curr. Pharm. Biotechnol. 2014, 15, 475–485. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Berania, I.; Cardin, G.B.; Clément, I.; Guertin, L.; Ayad, T.; Bissada, E.; Nguyen-Tan, P.F.; Filion, E.; Guilmette, J.; Gologan, O. Four PTEN-targeting co-expressed mi RNA s and ACTN 4-targeting mi R-548b are independent prognostic biomarkers in human squamous cell carcinoma of the oral tongue. Int. J. Cancer 2017, 141, 2318–2328. [Google Scholar] [CrossRef] [Green Version]
- Jin, Y.; Li, Y.; Wang, X.; Yang, Y. Dysregulation of MiR-519d affects oral squamous cell carcinoma invasion and metastasis by targeting MMP3. J. Cancer 2019, 10, 2720. [Google Scholar] [CrossRef] [Green Version]
- Zhao, Y.; Wang, P.; Wu, Q. miR-1278 sensitizes nasopharyngeal carcinoma cells to cisplatin and suppresses autophagy via targeting ATG2B. Mol. Cell. Probes 2020, 53, 101597. [Google Scholar] [CrossRef] [PubMed]
- Hamano, R.; Miyata, H.; Yamasaki, M.; Kurokawa, Y.; Hara, J.; ho Moon, J.; Nakajima, K.; Takiguchi, S.; Fujiwara, Y.; Mori, M. Overexpression of miR-200c induces chemoresistance in esophageal cancers mediated through activation of the Akt signaling pathway. Clin. Cancer Res. 2011, 17, 3029–3038. [Google Scholar] [CrossRef] [Green Version]
- Li, B.; Hong, P.; Zheng, C.-C.; Dai, W.; Chen, W.-Y.; Yang, Q.-S.; Han, L.; Tsao, S.W.; Chan, K.T.; Lee, N.P.Y. Identification of miR-29c and its target FBXO31 as a key regulatory mechanism in esophageal cancer chemoresistance: Functional validation and clinical significance. Theranostics 2019, 9, 1599. [Google Scholar] [CrossRef] [PubMed]
- Shi, J.; Bao, X.; Liu, Z.; Zhang, Z.; Chen, W.; Xu, Q. Serum miR-626 and miR-5100 are promising prognosis predictors for oral squamous cell carcinoma. Theranostics 2019, 9, 920. [Google Scholar] [CrossRef] [PubMed]
- Sannigrahi, M.K.; Sharma, R.; Singh, V.; Panda, N.K.; Rattan, V.; Khullar, M. Role of host miRNA hsa-mir-139-3p in hpv-16–induced carcinomas. Clin. Cancer Res. 2017, 23, 3884–3895. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hess, A.-K.; Müer, A.; Mairinger, F.D.; Weichert, W.; Stenzinger, A.; Hummel, M.; Budach, V.; Tinhofer, I. MiR-200b and miR-155 as predictive biomarkers for the efficacy of chemoradiation in locally advanced head and neck squamous cell carcinoma. Eur. J. Cancer 2017, 77, 3–12. [Google Scholar] [CrossRef] [PubMed]
- Just, C.; Knief, J.; Lazar-Karsten, P.; Petrova, E.; Hummel, R.; Röcken, C.; Wellner, U.; Thorns, C. MicroRNAs as potential biomarkers for chemoresistance in adenocarcinomas of the esophagogastric junction. J. Oncol. 2019, 2019, 4903152. [Google Scholar] [CrossRef] [Green Version]
- Qin, X.; Guo, H.; Wang, X.; Zhu, X.; Yan, M.; Wang, X.; Xu, Q.; Shi, J.; Lu, E.; Chen, W. Exosomal miR-196a derived from cancer-associated fibroblasts confers cisplatin resistance in head and neck cancer through targeting CDKN1B and ING5. Genome Biol. 2019, 20, 12. [Google Scholar] [CrossRef] [PubMed]
- Guan, G.-F.; Zhang, D.-J.; Wen, L.-J.; Xin, D.; Liu, Y.; Yu, D.-J.; Su, K.; Zhu, L.; Guo, Y.-Y.; Wang, K. Overexpression of lncRNA H19/miR-675 promotes tumorigenesis in head and neck squamous cell carcinoma. Int. J. Med Sci. 2016, 13, 914. [Google Scholar] [CrossRef] [Green Version]
- Song, J.; Zhang, N.; Cao, L.; Xiao, D.; Ye, X.; Luo, E.; Zhang, Z. Down-regulation of miR-200c associates with poor prognosis of oral squamous cell carcinoma. Int. J. Clin. Oncol. 2020, 25, 1072–1078. [Google Scholar] [CrossRef]
- Yu, E.-H.; Tu, H.-F.; Wu, C.-H.; Yang, C.-C.; Chang, K.-W. MicroRNA-21 promotes perineural invasion and impacts survival in patients with oral carcinoma. J. Chin. Med Assoc. 2017, 80, 383–388. [Google Scholar] [CrossRef]
- Tanaka, K.; Miyata, H.; Sugimura, K.; Fukuda, S.; Kanemura, T.; Yamashita, K.; Miyazaki, Y.; Takahashi, T.; Kurokawa, Y.; Yamasaki, M. miR-27 is associated with chemoresistance in esophageal cancer through transformation of normal fibroblasts to cancer-associated fibroblasts. Carcinogenesis 2015, 36, 894–903. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Arantes, L.M.R.B.; Laus, A.C.; Melendez, M.E.; de Carvalho, A.C.; Sorroche, B.P.; De Marchi, P.R.M.; Evangelista, A.F.; Scapulatempo-Neto, C.; de Souza Viana, L.; Carvalho, A.L. MiR-21 as prognostic biomarker in head and neck squamous cell carcinoma patients undergoing an organ preservation protocol. Oncotarget 2017, 8, 9911. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chang, Y.-C.; Jan, C.-I.; Peng, C.-Y.; Lai, Y.-C.; Hu, F.-W.; Yu, C.-C. Activation of microRNA-494-targeting Bmi1 and ADAM10 by silibinin ablates cancer stemness and predicts favourable prognostic value in head and neck squamous cell carcinomas. Oncotarget 2015, 6, 24002. [Google Scholar] [CrossRef] [PubMed]
- Tu, H.-F.; Liu, C.-J.; Chang, C.-L.; Wang, P.-W.; Kao, S.-Y.; Yang, C.-C.; Yu, E.-H.; Lin, S.-C.; Chang, K.-W. The association between genetic polymorphism and the processing efficiency of miR-149 affects the prognosis of patients with head and neck squamous cell carcinoma. PLoS ONE 2012, 7, e51606. [Google Scholar] [CrossRef]
- Klussmann, J.P. Head and neck cancer-new insights into a heterogeneous disease. Oncol. Res. Treat. 2017, 40, 318–319. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ahmad, P.; Sana, J.; Slávik, M.; Gurín, D.; Radová, L.; Gablo, N.A.; Kazda, T.; Smilek, P.; Horáková, Z.; Gal, B. MicroRNA-15b-5p predicts locoregional relapse in head and neck carcinoma patients treated with intensity-modulated radiotherapy. Cancer Genom. Proteom. 2019, 16, 139–146. [Google Scholar] [CrossRef] [Green Version]
- Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2021, 71, 209–249. [Google Scholar] [CrossRef]
- Iarc, W. GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. 2012. Available online: https://gco.iarc.fr/ (accessed on 15 September 2021).
- Lambert, R.; Sauvaget, C.; de Camargo Cancela, M.; Sankaranarayanan, R. Epidemiology of cancer from the oral cavity and oropharynx. Eur. J. Gastroenterol. Hepatol. 2011, 23, 633–641. [Google Scholar] [CrossRef]
- Shen, D.-W.; Pouliot, L.M.; Hall, M.D.; Gottesman, M.M. Cisplatin resistance: A cellular self-defense mechanism resulting from multiple epigenetic and genetic changes. Pharmacol. Rev. 2012, 64, 706–721. [Google Scholar] [CrossRef] [Green Version]
- Forastiere, A.A.; Ang, K.; Brizel, D.; Brockstein, B.E.; Dunphy, F.; Eisele, D.W.; Goepfert, H.; Hicks, W.L.; Kies, M.S.; Lydiatt, W.M. Head and neck cancers: Clinical practice guidelines. JNCCN J. Natl. Compr. Cancer Netw. 2005, 3, 316–391. [Google Scholar]
- Zibelman, M.; Mehra, R. Overview of current treatment options and investigational targeted therapies for locally advanced squamous cell carcinoma of the head and neck. Am. J. Clin. Oncol. 2016, 39, 396–406. [Google Scholar] [CrossRef]
- Moher, D.; Shamseer, L.; Clarke, M.; Ghersi, D.; Liberati, A.; Petticrew, M.; Shekelle, P.; Stewart, L.A. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst. Rev. 2015, 4, 1. [Google Scholar] [CrossRef] [Green Version]
- Health NIo. Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies: National Heart, Lung, and Blood Institute. Available online: https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools (accessed on 10 December 2021).
- Cochran, W.G. The combination of estimates from different experiments. Biometrics 1954, 10, 101–129. [Google Scholar] [CrossRef]
- Higgins, J.P.; Thompson, S.G.; Deeks, J.J.; Altman, D.G. Measuring inconsistency in meta-analyses. BMJ 2003, 327, 557–560. [Google Scholar] [CrossRef] [Green Version]
- Egger, M.; Smith, G.D.; Schneider, M.; Minder, C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315, 629–634. [Google Scholar] [CrossRef] [Green Version]
- Orwin, R.G. A fail-safe N for effect size in meta-analysis. J. Educ. Stat. 1983, 8, 157–159. [Google Scholar] [CrossRef]
- Duval, S.; Tweedie, R. A nonparametric “trim and fill” method of accounting for publication bias in meta-analysis. J. Am. Stat. Assoc. 2000, 95, 89–98. [Google Scholar]
- Biamonte, F.; Santamaria, G.; Sacco, A.; Perrone, F.M.; Di Cello, A.; Battaglia, A.M.; Salatino, A.; Di Vito, A.; Aversa, I.; Venturella, R. MicroRNA let-7g acts as tumor suppressor and predictive biomarker for chemoresistance in human epithelial ovarian cancer. Sci. Rep. 2019, 9, 5668. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Magee, P.; Shi, L.; Garofalo, M. Role of microRNAs in chemoresistance. Ann. Transl. Med. 2015, 3, 332. [Google Scholar] [PubMed]
- Dai, F.; Dai, L.; Zheng, X.; Guo, Y.; Zhang, Y.; Niu, M.; Lu, Y.; Li, H.; Hou, R.; Zhang, Y. Non-coding RNAs in drug resistance of head and neck cancers: A review. Biomed. Pharmacother. 2020, 127, 110231. [Google Scholar] [CrossRef] [PubMed]
S No. | Search Items |
---|---|
1. | “miRNA” AND “treatment” OR drug resistance” AND “HNC” OR “Head and Neck Cancer” |
2. | “microRNA” AND “drug resistance” AND “HNC” OR “Head and Neck Cancer” |
3. | “Up-regulation OR down-regulation in HNC” OR “Differential Expression” OR “Deregulated miRNAs “OR “Head and Neck Cancer” |
4. | “miRNA” AND “chemotherapeutic resistance” OR “chemosensitivity” AND “HNC” OR “Head and Neck Cancer” |
5. | “miRNA” AND “treatment resistance” OR “chemoresistance” AND “HNC” OR “Head and Neck Cancer” |
6. | “microRNA” AND “chemosensitivity” AND “HNC” OR “Head and Neck Cancer” |
7. | “microRNA” AND “chemoresistance” AND “HNC” OR “Head and Neck Cancer” |
8. | “HNC survival outcome” OR “Hazard Ratio” AND “HNC” OR “Head and Neck Cancer” |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Shaw, P.; Raymond, G.; Senthilnathan, R.; Kumarasamy, C.; Baxi, S.; Suresh, D.; Shetty, S.; Ram M, R.; Chandramoorthy, H.C.; Sivanandy, P.; et al. Clinical Theragnostic Relationship between Chemotherapeutic Resistance, and Sensitivity and miRNA Expressions in Head and Neck Cancers: A Systematic Review and Meta-Analysis Protocol. Genes 2021, 12, 2029. https://0-doi-org.brum.beds.ac.uk/10.3390/genes12122029
Shaw P, Raymond G, Senthilnathan R, Kumarasamy C, Baxi S, Suresh D, Shetty S, Ram M R, Chandramoorthy HC, Sivanandy P, et al. Clinical Theragnostic Relationship between Chemotherapeutic Resistance, and Sensitivity and miRNA Expressions in Head and Neck Cancers: A Systematic Review and Meta-Analysis Protocol. Genes. 2021; 12(12):2029. https://0-doi-org.brum.beds.ac.uk/10.3390/genes12122029
Chicago/Turabian StyleShaw, Peter, Greg Raymond, Raghul Senthilnathan, Chellan Kumarasamy, Siddhartha Baxi, Deepa Suresh, Sameep Shetty, Ravishankar Ram M, Harish C. Chandramoorthy, Palanisamy Sivanandy, and et al. 2021. "Clinical Theragnostic Relationship between Chemotherapeutic Resistance, and Sensitivity and miRNA Expressions in Head and Neck Cancers: A Systematic Review and Meta-Analysis Protocol" Genes 12, no. 12: 2029. https://0-doi-org.brum.beds.ac.uk/10.3390/genes12122029